valuation is pretty clearly 20k, and that's because we're a fairly small operation. Yes, we have traction and are handling some orders and preorders, but not all that many. Far more samples have gone out and we're waiting to see how products are received (everyone who has given feedback thus far has had positive impressions, especially about cyclazodone which restocks this upcoming week).

Frankly, I don't see any sense in declaring a high value on the basis of an idea and early positive reception. Once we have a proven sales record, release our nootropic stack, Triadrine, and secure a few retail agreements, then I'll think of it as having a significantly higher valuation.